IMMX

Immix Biopharma, Inc. (IMMX) | Rumor.io

Immix Biopharma

IMMX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,353

Bullish sentiment (50-day avg)88%

Price to earnings ratio-12.9

Market capitalization820.6M

Earnings per share-0.88

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-29.4M

Social

What share of all stock conversation is about IMMX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.03	0% +0	0% 0	0.01% +0

Sep 29

The company, Immix Biopharma, has announced positive results for its NXC-201 therapy, with an 89% complete response rate in an interim update across all 45 patients in the NEXICART-2 trial, and 25 new relapsed/refractory AL Amyloidosis patients either in complete response or already minimum residual disease-negative.
The therapy has shown excellent durability, with no relapses observed in patients who reached complete response or minimum residual disease-negativity, and no neurotoxicity or enterocolitis observed in the trial.
The company has priced a $125M offering at $11 per share, and analysts have raised their price target from $21 to $30, with Needham reiterating a Buy recommendation, citing the therapy's potential as a best-in-class treatment for AL Amyloidosis.

Generated by AI

Sentiment

Of the messages about IMMX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	85.25%	62.07% -37.25	91.99% +6.4
Bearish	0% 0	14.75%	37.93% +37.25	8.01% -6.4

Bullish· Sep 29

The company has secured $125M in fresh capital through an offering at $11 per share, which is seen as a validation of the asset's value and a strong financial position for the company.
Needham has raised its price target for IMMX from $21 to $30, and Bank of America has also increased its price target to $30, while maintaining a "Buy" rating, indicating a high level of confidence in the asset's growth potential.
The recent offering has brought in new and existing institutional investors, including Eventide, Janus Henderson, and Ridgeback, which is seen as a positive sign for the company's future prospects and a potential catalyst for future growth.

Bearish· May 21

The company's strategy is not making sense, treating the business like a science experiment rather than a for-profit public company.
The stock's recent move up is seen as a half-hearted gap, potentially a sign of a halt waiting to happen or a Tuesday move.
The company needs to spend money to create the product, which could lead to a short-lived blip on the radar before the stock bounces back.

Generated by AI

Topics

Of the messages about IMMX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	56.52%	0.94%
Technical Analysis	0%	0%	2.17%	0.16%
Analysts	50%	50%	19.57%	49.46%
Controversies	0%	0%	21.74%	0.12%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	49.32%

Announcements· May 22

Immix Biopharma, Inc. (IMMX) announced positive clinical results for its NXC-201 treatment in a Phase 1b/2a clinical trial, achieving a 100% overall response rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with zero ICANS.
The NEXICART-1 study demonstrated a 100% overall response rate and 63% complete response rate, showing promising results for the treatment of relapsed or refractory multiple myeloma and AL Amyloidosis.
IMMX's stock price surged by up to 28% premarket and continued to rise, reaching a 20.73% increase, following the announcement of the positive clinical results.

Technical Analysis· Jul 13

The 20 EMA crossing above the 50 EMA on IMMX's 1H chart suggests accelerating momentum, with a follow-through above the midday high expected to confirm the trend.
The volume spike on IMMX's breakout validates buyers, with a stop set below the breakout level to manage risk, and the odds favoring continuation if the price holds above the breakout zone.
The golden cross formed on IMMX's chart, with the 50 SMA crossing above the 200 SMA, signals a medium-term bullish bias, with the RSI climbing but under 70, indicating room to run in the uptrend.

Generated by AI

Community

Of the messages about IMMX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.89%	90.98%	86.4%	10.47%
Newcomers	11.11%	9.02%	13.6%	89.53%

Regulars· Sep 29

The company's asset, NXC-201, has shown promising results with an 89% complete response rate in an interim update across all 45 patients, making it a potential best-in-class therapy for AL Amyloidosis.
Management's decision to raise capital at $11 per share may be seen as dilutive, but the company is well-financed and has a strong pipeline, with a potential 98% CR rate and no relapses observed in patients who reached CR or MRD-negativity.
The recent $125M offering has been met with positive analyst commentary, with Needham raising its price target from $21 to $30 and reiterating a Buy rating, and the company is on track to meet its targets with a potential $3 billion gross profit and $2.8 billion earnings.

Newcomers· Jul 20

The Chief Medical Officer (CMO) of Immix Biopharma, Ronald Fischer, is a fugitive who fled while on trial for sexual assault two decades ago.
The hiring of Fischer without proper due diligence has raised concerns about the company's credibility and may have contributed to the stock's decline.
The company's stock price has dropped significantly after the news broke, with some investors selling their positions and others expressing skepticism about the company's future.

Generated by AI

News

Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating

15d agoYahoo Finance

Also Discussed

Investors talking about IMMX also mention

#	Name	Attention
1	Nutriband Inc.NTRB	0%0
2	Biofrontera Inc.BFRI	0%0
3	Society Pass IncorporatedSOPA	0%0
4	Longeveron Inc. Class A Common StockLGVN	0%0
5	TSRI - TSR, Inc.	——
6	Pasithea Therapeutics Corp.KTTA	0%0
7	ALLK - Allakos Inc.	——
8	PTPI - Petros Pharmaceuticals, Inc.	——
9	Kidpik Corp.PIK	0%new
10	Ensysce Biosciences, Inc. Common StockENSC	0%0

Immix Biopharma, Inc.

Healthcare
Biotechnology

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors. The company also works on immune-dysregulated and inflammatory diseases through its proprietary therapeutic platforms. Immix Biopharma operates in the biotechnology sector, where its role is centered on advancing investigational treatments designed to address high-unmet-need conditions through cell therapy and precision drug delivery approaches. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma is positioned as a development-stage company focused on translating specialized oncology and immunology research into clinical programs.

Website

Location

11400 West Olympic Boulevard

Los Angeles, CA, 90064

United States

Social

What share of all stock conversation is about IMMX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.03	0% +0	0% 0	0.01% +0

Sep 29

The company, Immix Biopharma, has announced positive results for its NXC-201 therapy, with an 89% complete response rate in an interim update across all 45 patients in the NEXICART-2 trial, and 25 new relapsed/refractory AL Amyloidosis patients either in complete response or already minimum residual disease-negative.
The therapy has shown excellent durability, with no relapses observed in patients who reached complete response or minimum residual disease-negativity, and no neurotoxicity or enterocolitis observed in the trial.
The company has priced a $125M offering at $11 per share, and analysts have raised their price target from $21 to $30, with Needham reiterating a Buy recommendation, citing the therapy's potential as a best-in-class treatment for AL Amyloidosis.

Generated by AI

Sentiment

Of the messages about IMMX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	85.25%	62.07% -37.25	91.99% +6.4
Bearish	0% 0	14.75%	37.93% +37.25	8.01% -6.4

Bullish· Sep 29

The company has secured $125M in fresh capital through an offering at $11 per share, which is seen as a validation of the asset's value and a strong financial position for the company.
Needham has raised its price target for IMMX from $21 to $30, and Bank of America has also increased its price target to $30, while maintaining a "Buy" rating, indicating a high level of confidence in the asset's growth potential.
The recent offering has brought in new and existing institutional investors, including Eventide, Janus Henderson, and Ridgeback, which is seen as a positive sign for the company's future prospects and a potential catalyst for future growth.

Bearish· May 21

The company's strategy is not making sense, treating the business like a science experiment rather than a for-profit public company.
The stock's recent move up is seen as a half-hearted gap, potentially a sign of a halt waiting to happen or a Tuesday move.
The company needs to spend money to create the product, which could lead to a short-lived blip on the radar before the stock bounces back.

Generated by AI

Topics

Of the messages about IMMX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	56.52%	0.94%
Technical Analysis	0%	0%	2.17%	0.16%
Analysts	50%	50%	19.57%	49.46%
Controversies	0%	0%	21.74%	0.12%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	49.32%

Announcements· May 22

Immix Biopharma, Inc. (IMMX) announced positive clinical results for its NXC-201 treatment in a Phase 1b/2a clinical trial, achieving a 100% overall response rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with zero ICANS.
The NEXICART-1 study demonstrated a 100% overall response rate and 63% complete response rate, showing promising results for the treatment of relapsed or refractory multiple myeloma and AL Amyloidosis.
IMMX's stock price surged by up to 28% premarket and continued to rise, reaching a 20.73% increase, following the announcement of the positive clinical results.

Technical Analysis· Jul 13

The 20 EMA crossing above the 50 EMA on IMMX's 1H chart suggests accelerating momentum, with a follow-through above the midday high expected to confirm the trend.
The volume spike on IMMX's breakout validates buyers, with a stop set below the breakout level to manage risk, and the odds favoring continuation if the price holds above the breakout zone.
The golden cross formed on IMMX's chart, with the 50 SMA crossing above the 200 SMA, signals a medium-term bullish bias, with the RSI climbing but under 70, indicating room to run in the uptrend.

Generated by AI

Community

Of the messages about IMMX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.89%	90.98%	86.4%	10.47%
Newcomers	11.11%	9.02%	13.6%	89.53%

Regulars· Sep 29

The company's asset, NXC-201, has shown promising results with an 89% complete response rate in an interim update across all 45 patients, making it a potential best-in-class therapy for AL Amyloidosis.
Management's decision to raise capital at $11 per share may be seen as dilutive, but the company is well-financed and has a strong pipeline, with a potential 98% CR rate and no relapses observed in patients who reached CR or MRD-negativity.
The recent $125M offering has been met with positive analyst commentary, with Needham raising its price target from $21 to $30 and reiterating a Buy rating, and the company is on track to meet its targets with a potential $3 billion gross profit and $2.8 billion earnings.

Newcomers· Jul 20

The Chief Medical Officer (CMO) of Immix Biopharma, Ronald Fischer, is a fugitive who fled while on trial for sexual assault two decades ago.
The hiring of Fischer without proper due diligence has raised concerns about the company's credibility and may have contributed to the stock's decline.
The company's stock price has dropped significantly after the news broke, with some investors selling their positions and others expressing skepticism about the company's future.

Generated by AI

Immix Biopharma

Social

Sep 29

Bullish· Sep 29

Bearish· May 21

Announcements· May 22

Technical Analysis· Jul 13

Regulars· Sep 29

Newcomers· Jul 20

Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial

Immix posts new trial data for AL amyloidosis drug (IMMX)

Immix Biopharma reports 89% complete response rate in trial

Immix Biopharma prices $125M stock offering at $11 per share

Mizuho raises Immix Biopharma stock price target to $26 on expansion

Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating

Also Discussed

Immix Biopharma, Inc.

Company Information

Location

Social

Sep 29

Bullish· Sep 29

Bearish· May 21

Announcements· May 22

Technical Analysis· Jul 13

Regulars· Sep 29

Newcomers· Jul 20

Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial

Immix posts new trial data for AL amyloidosis drug (IMMX)

Immix Biopharma reports 89% complete response rate in trial

Immix Biopharma prices $125M stock offering at $11 per share

Mizuho raises Immix Biopharma stock price target to $26 on expansion

Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating

Also Discussed